Form 4: Director William Young Receives Equity Grant at Praxis

Director William D. Young was granted 1,371 restricted stock units and 648 stock options by Praxis Precision Medicines.

Summary

• Director William D. Young acquired 1,371 restricted stock units (RSUs) on June 10, 2026.
• The RSUs represent a contingent right to receive one share of common stock each and vest on June 10, 2027, or the date of the 2027 annual meeting.
• Director Young was also granted 648 stock options with an exercise price of $240.66.
• The stock options vest in twelve equal monthly installments starting July 10, 2026, through June 10, 2027.
• Following these transactions, the director's direct beneficial ownership of common stock increased to 3,269 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company strategy or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.
• Standard retention and incentive structure for board members.

Negatives

• Dilutive impact of new equity grants on existing shareholders, though minimal in scale.

Risks

• Market volatility affecting the value of granted equity.
• Performance risk associated with the company's ability to meet milestones required for stock appreciation.

Future Outlook

The equity grants are subject to standard vesting schedules over the next 12 months, aligning the director's tenure with the company's upcoming annual meeting cycle.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure director retention and alignment with long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of RSU and option-based compensation is consistent with standard corporate governance practices for mid-cap biotechnology firms.
• Vesting schedules tied to annual meetings are common among U.S.-listed life sciences companies.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of stock options beginning July 10, 2026.
• Vesting of restricted stock units on June 10, 2027.

Key Dates

Keywords

Praxis Precision Medicines, PRAX, Form 4, Insider Trading, Equity Compensation, Director Compensation